The cell and gene therapy group initially licensed its LentiVector platform to Novartis in the CAR-T field in October 2014, followed by a five year commercial supply agreement signed in December 2019.
The new deal extends the agreement to the end of 2028, with Oxford Biomedica regaining its rights to the LentiVector platform relating to three CAR-T targets, including CD19 targeted therapies. It also has the right to work with partners other than Novartis across CAR-T targets.
Novartis will benefit from additional flexibility in ordering; with the removal of a minimum order agreement.
The two companies continue to work together on CAR-T programs, including Novartis’ Kymriah.
Arcellx agreement
Meanwhile, Oxford Biomedica has also announced a new licence and supply agreement with Gaithersburg MD biotech Arcellx, Inc.
Arcellx, a clinical stage biopharma company developing novel, adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases, will gain a non-exclusive licence to the LentiVector platform for application in select Arcellx CAR-T programs with a three-year clinical supply agreement.
Oxford Biomedica will receive payments related to the development and manufacturing of lentiviral vectors for use in clinical trials. Additionally, the agreement allows for payments to Oxford Biomedica for the manufacture and supply of lentiviral vectors for commercial use.
